A Clinical Randomized Trial: Effects of Early Application of Sacubitril/valsartan on Ventricular Remodeling and Prognosis in Acute Myocardial Infarction Patients

Overview

Journal Contemp Clin Trials Commun

Date 2024 Oct 11

PMID 39391226

Authors

Zhengfeng Liu

Kun Cui

Guangdong Wang

Wenqing Jin

Qiong Yao

Yuanzheng Zhang

Affiliations

Soon will be listed here.

Abstract

Objectives: To explore the effects of early application of sacubitril/valsartan on ventricular remodeling and prognosis in patients with acute myocardial infarction (AMI).

Methods: Total of 295 patients with AMI admitted to the hospital were enrolled between August 2019 and August 2021. According to different treatment methods, they were divided into observation group (sacubitril/valsartan sodium tables combined with standard treatment, 132 patients) and control group (benazepril hydrochloride tablets combined with standard treatment, 163 patients). The levels of plasma N-terminal pro-brain natriuretic peptide (NT-proBNP), creatinine (Cr) and serum K before and at 6 months after treatment, standard deviation of all normal-to-normal intervals (SDNN), standard deviation of the average all normal-to-normal intervals (SDANN), root mean square of differences between adjacent normal-to-normal intervals/root mean square differences of successive R-R (RMSSD), left ventricular end-diastolic volume (LVEDV), left ventricular ejection fraction (LVEF) and left ventricular end-systolic volume (LVESV) in the two groups were compared. The adverse reactions during treatment and major adverse cardiac events (MACE) during 6 months of follow-up in both groups were statistically analyzed.

Results: The levels of NT-proBNP, Cr and K, LVEDV and LVESV in observation group were significantly lower than those in control group ( < 0.05), while LVEF, SDNN, SDANN and RMSSD were significantly higher than those in control group ( < 0.05). The incidence of MACE in observation group was lower than that in control group during 6 months of follow-up (7.58 % 27.61 %, < 0.05), but there was no significant difference in the incidence of adverse reactions (9.85 % 12.88 %, > 0.05).

Conclusion: Early application of sacubitril/valsartan sodium can effectively delay ventricular remodeling, improve cardiac function and heart rate variability indexes, reduce NT-proBNP level and improve prognosis in AMI patients.

Citing Articles

Predicting the risk of heart failure after acute myocardial infarction using an interpretable machine learning model.

Lin Q, Zhao W, Zhang H, Chen W, Lian S, Ruan Q Front Cardiovasc Med. 2025; 12:1444323.

PMID: 39925976 PMC: 11802525. DOI: 10.3389/fcvm.2025.1444323.

References

Sauer A, Cole R, Jensen B, Pal J, Sharma N, Yehya A . Practical guidance on the use of sacubitril/valsartan for heart failure. Heart Fail Rev. 2018; 24(2):167-176. PMC: 6394573. DOI: 10.1007/s10741-018-9757-1. View

Ledwidge M, Dodd J, Ryan F, Sweeney C, McDonald K, Fox R . Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre-Heart Failure With Preserved Ejection Fraction: The PARABLE Randomized Clinical Trial. JAMA Cardiol. 2023; 8(4):366-375. PMC: 9996460. DOI: 10.1001/jamacardio.2023.0065. View

Pfeffer M, Claggett B, Lewis E, Granger C, Kober L, Maggioni A . Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. N Engl J Med. 2021; 385(20):1845-1855. DOI: 10.1056/NEJMoa2104508. View

Al-Lamee R, Nowbar A, Francis D . Percutaneous coronary intervention for stable coronary artery disease. Heart. 2018; 105(1):11-19. DOI: 10.1136/heartjnl-2017-312755. View

Zimbardo G, Cialdella P, Di Giusto F, Migliaro S, Anastasia G, Petrolati E . Physiological assessment after percutaneous coronary intervention: the hard truth. Panminerva Med. 2021; 63(4):519-528. DOI: 10.23736/S0031-0808.21.04363-9. View

Pezel T, Viallon M, Croisille P, Sebbag L, Bochaton T, Garot J . Imaging Interstitial Fibrosis, Left Ventricular Remodeling, and Function in Stage A and B Heart Failure. JACC Cardiovasc Imaging. 2020; 14(5):1038-1052. DOI: 10.1016/j.jcmg.2020.05.036. View

Edupuganti M, Ganga V . Acute myocardial infarction in pregnancy: Current diagnosis and management approaches. Indian Heart J. 2020; 71(5):367-374. PMC: 7013191. DOI: 10.1016/j.ihj.2019.12.003. View

Tocci G . Antihypertensive Efficacy of LCZ696 (Sacubitril/Valsartan) in Hypertension. Cardiology. 2020; 145(9):599-600. DOI: 10.1159/000508345. View

Espinola-Zavaleta N, Antonio-Villa N, Briseno-Diaz N, Oregel-Camacho D, Camacho-Camacho G, Keirns C . Left ventricular and atrial global strain evaluation within subtypes of ventricular remodeling. Echocardiography. 2021; 38(2):280-288. DOI: 10.1111/echo.14981. View

10.

De Vecchis R, Ariano C, Soreca S . Antihypertensive effect of sacubitril/valsartan: a meta-analysis. Minerva Cardioangiol. 2019; 67(3):214-222. DOI: 10.23736/S0026-4725.19.04869-2. View

11.

Kapur N, Thayer K, Zweck E . Cardiogenic Shock in the Setting of Acute Myocardial Infarction. Methodist Debakey Cardiovasc J. 2020; 16(1):16-21. PMC: 7137623. DOI: 10.14797/mdcj-16-1-16. View

12.

Bhagat A, Greene S, Vaduganathan M, Fonarow G, Butler J . Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization. JACC Heart Fail. 2018; 7(1):1-12. PMC: 8053043. DOI: 10.1016/j.jchf.2018.06.011. View

13.

Docherty K, Vaduganathan M, Solomon S, McMurray J . Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF. JACC Heart Fail. 2020; 8(10):800-810. PMC: 8837825. DOI: 10.1016/j.jchf.2020.06.020. View

14.

Zhao J, Zeng Y, Shen X . Efficacy and safety of early initiation of Sacubitril/Valsartan in patients after acute myocardial infarction: A meta-analysis. Clin Cardiol. 2021; 44(10):1354-1359. PMC: 8495087. DOI: 10.1002/clc.23717. View

15.

Solomon S, Vaduganathan M, Claggett B, Packer M, Zile M, Swedberg K . Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Circulation. 2019; 141(5):352-361. DOI: 10.1161/CIRCULATIONAHA.119.044586. View

16.

Peng S, Lu X, Qi Y, Li J, Xu J, Yuan T . LCZ696 Ameliorates Oxidative Stress and Pressure Overload-Induced Pathological Cardiac Remodeling by Regulating the Sirt3/MnSOD Pathway. Oxid Med Cell Longev. 2020; 2020:9815039. PMC: 7519988. DOI: 10.1155/2020/9815039. View

17.

Martin N, Manoharan K, Davies C, Lumbers R . Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Cochrane Database Syst Rev. 2021; 5:CD012721. PMC: 8140651. DOI: 10.1002/14651858.CD012721.pub3. View

18.

Safi S, Sethi N, Nielsen E, Feinberg J, Jakobsen J, Gluud C . Beta-blockers for suspected or diagnosed acute myocardial infarction. Cochrane Database Syst Rev. 2019; 12:CD012484. PMC: 6915833. DOI: 10.1002/14651858.CD012484.pub2. View

19.

Moon M, Hwang I, Lee H, Kim S, Yoon Y, Park J . Reverse Remodeling Assessed by Left Atrial and Ventricular Strain Reflects Treatment Response to Sacubitril/Valsartan. JACC Cardiovasc Imaging. 2022; 15(9):1525-1541. DOI: 10.1016/j.jcmg.2022.03.019. View

20.

Main A, Saw J . Percutaneous Coronary Intervention for the Treatment of Spontaneous Coronary Artery Dissection. Interv Cardiol Clin. 2019; 8(2):199-208. DOI: 10.1016/j.iccl.2018.11.008. View